Expert Ratings for Cytokinetics
Portfolio Pulse from Benzinga Insights
Cytokinetics (NASDAQ:CYTK) has received positive analyst ratings in the last quarter, with 2 bullish and 5 somewhat bullish ratings. No bearish or indifferent ratings were observed. The average 12-month price target for the company is $60.29, which has increased by 1.33% over the past month.
October 09, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cytokinetics has received positive analyst ratings, which could boost investor confidence and potentially drive the stock price up in the short term.
Analyst ratings often influence investor sentiment. The positive ratings for Cytokinetics indicate a favorable outlook for the company, which could lead to increased demand for the stock and potentially drive up the price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100